Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Lang

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Cancer Immunology, Immunotherapy : CII|June 5, 2008
MHC-dependent desensitization of intrinsic anti-self reactivityCristan M Jubala, Angela R Lamerato-Kozicki, Michelle Borakove, et al.
Immunological Reviews|February 14, 2004
Tolerance-induced receptor selection: scope, sensitivity, locus specificity, and relationship to lymphocyte-positive selectionDjemel Aït-Azzouzene, Patrick Skog, Marc Retter, et al.
Frontiers in Immunology|February 21, 2022
Elevated Detection of Dual Antibody B Cells Identifies Lupus Patients With B Cell-Reactive VH4-34 AutoantibodiesJacob N Peterson, Susan A Boackle, Sophina H Taitano, et al.
BMC Cancer|November 5, 2020
RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast CancerJohn J Tentler, Julie Lang, Anna Capasso, et al.
Nature Communications|June 1, 2019
Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapyJennifer L Caswell-Jin, Katherine McNamara, Johannes G Reiter, et al.
Nature Communications|February 10, 2019
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapyJennifer L Caswell-Jin, Katherine McNamara, Johannes G Reiter, et al.
The Journal of Clinical Endocrinology and Metabolism|September 13, 2019
Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor MicroenvironmentJulie Lang, Anna Capasso, Kimberly R Jordan, et al.
Frontiers in Oncology|November 24, 2022
Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse modelsJulie Lang, Alexis D Leal, Juan A Marín-Jiménez, et al.
Cancer Research Communications|October 31, 2025
Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal CancerRobert W Lentz, Julie Lang, Todd M Pitts, et al.
BMJ Open|June 6, 2022
I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operationsDaniel Clark Files, Michael A Matthay, Carolyn S Calfee, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Cancer Immunology, Immunotherapy : CII|June 5, 2008
MHC-dependent desensitization of intrinsic anti-self reactivityCristan M Jubala, Angela R Lamerato-Kozicki, Michelle Borakove, et al.
Immunological Reviews|February 14, 2004
Tolerance-induced receptor selection: scope, sensitivity, locus specificity, and relationship to lymphocyte-positive selectionDjemel Aït-Azzouzene, Patrick Skog, Marc Retter, et al.
Frontiers in Immunology|February 21, 2022
Elevated Detection of Dual Antibody B Cells Identifies Lupus Patients With B Cell-Reactive VH4-34 AutoantibodiesJacob N Peterson, Susan A Boackle, Sophina H Taitano, et al.
BMC Cancer|November 5, 2020
RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast CancerJohn J Tentler, Julie Lang, Anna Capasso, et al.
Nature Communications|June 1, 2019
Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapyJennifer L Caswell-Jin, Katherine McNamara, Johannes G Reiter, et al.
Nature Communications|February 10, 2019
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapyJennifer L Caswell-Jin, Katherine McNamara, Johannes G Reiter, et al.
The Journal of Clinical Endocrinology and Metabolism|September 13, 2019
Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor MicroenvironmentJulie Lang, Anna Capasso, Kimberly R Jordan, et al.
Frontiers in Oncology|November 24, 2022
Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse modelsJulie Lang, Alexis D Leal, Juan A Marín-Jiménez, et al.
Cancer Research Communications|October 31, 2025
Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal CancerRobert W Lentz, Julie Lang, Todd M Pitts, et al.
BMJ Open|June 6, 2022
I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operationsDaniel Clark Files, Michael A Matthay, Carolyn S Calfee, et al.
Pageof 6